Laurent Pharmaceuticals announces initiation of a Phase 1 clinical study of Fenretinide in Cystic Fibrosis Read more: http://www.digitaljournal.com/pr/1932533#ixzz32lRdzFo3

Laurent Pharmaceuticals Inc. announced today that the Research Institute of the McGill University Health Centre (RI-MUHC) has started enrolling patients in an investigator-initiated clinical trial evaluating the safety, tolerability and pharmacokinetics of a novel oral formulation of Fenretinide in adult subjects with … Continued

Efficacy and tolerability of a new nasal spray formulation containing hyaluronate and tobramycin in cystic fibrosis patients with bacterial rhinosinusitis

BACKGROUND: Chronic rhinosinusitis is common in cystic fibrosis (CF), as CFTR defects equally affect the airway and sinonasal mucosa. However, therapeutic strategies for CF-associated chronic rhinosinusitis lag behind current approaches for pulmonary disease. OBJECTIVE: To assess the tolerability and efficacy … Continued